CYP2C8 SLCO1B1 Variants Impact Response to Rosiglitazone
Genetic variants have clinical impact on response to rosiglitazone, but not pioglitazone
FRIDAY, June 10, 2016 (HealthDay News) -- Genetic variants in CYP2C8 and SLCO1B1 impact the therapeutic response to rosiglitazone in patients with type 2 diabetes, according to a study published online June 6 in Diabetes Care.
Adem Y. Dawed, M.P.H., from the University of Dundee in the United Kingdom, and colleagues genotyped 833 Scottish patients with type 2 diabetes treated with pioglitazone or rosiglitazone. The authors examined the correlation between variants in the SLCO1B1 and CYP2C8 genes (involved in transport and metabolism of thiazolidinediones) and therapeutic outcomes.
The researchers found that there was a correlation between the CYP2C8*3 variant and reduced glycemic response to rosiglitazone and less weight gain (P = 0.01 and 0.02, respectively). Enhanced glycemic response to rosiglitazone was seen in association with the SLCO1B1 521T>C variant (P = 0.04). Compared with poor responders, super responders, defined by combined genotypes at CYP2C8 and SLCO1B1 had a 0.39 percent greater reduction in glycated hemoglobin (P = 0.006). There was no significant impact for either variant with pioglitazone response.
"These results show that variants in CYP2C8 and SLCO1B1 have a large clinical impact on the therapeutic response to rosiglitazone and highlight the importance of studying transporter and metabolizing genes together in pharmacogenetics," the authors write.